左西孟旦治疗高龄老年难治性心力衰竭的临床评价  

Clinical evaluation of levosimendan in treatment of very elderly patients with refractory heart failure

作　　者：李丽[1] 

机构地区：[1]山东省淄博市中心医院老年病科,山东淄博255036

出　　处：《中国现代医生》2015年第24期93-95,共3页China Modern Doctor

摘　　要：目的探讨左西孟旦治疗高龄老年心力衰竭的临床治疗效果。方法选取我院自2012年6月～2013年10月期间收治的80例高龄老年心力衰竭患者作为研究对象，随机分为实验组以及对照组，每组40例，对照组采用米力农治疗，实验组使用左西孟旦治疗，比较两组的临床疗效。结果实验组患者的临床疗效以及收缩压、心率、心脏彩超LVEF、脑钠肽的变化差异、治疗前后血流动力学的变化差异均显著优于对照组，且不良反应显著低于对照组（P〈0．05）。结论左西孟旦治疗高龄老年心力衰竭具有显著的临床疗效，且不良反应少，值得在临床上广泛推广。Objective To investigate and explore the clinical treatment effects of levosimendan on the very elderly patients with heart failure. Methods Eighty very elderly patients with heart failure treated in our hospital from June 2012 to October 2013 were selected as the study subjects and randomly divided into the experimental group and the control group, with 40 patients in each group. The control group was given milrinone treatment and the experimental group was given levosimendan treatment. The clinical efficacy of the two groups was compared. Results The clinical efficacy and the changes of systolic blood pressure, heart rate, echocardiographic LVEF and brain natriuretic peptide of the experimental group were significantly better than the control group, and the adverse reactions of experimental group was significantly lower than the control group, with statistical significance（P〈0.05）. Conclusion In the treatment of elderly patients with heart failure, levosimendan shows remarkable clinical efficacy and causes low occurrence probability of adverse reactions, thereby worthy of wide clinical promotion.

关 键 词：左西孟旦 高龄老年 心力衰竭 脑钠肽 

分 类 号：R541.6[医药卫生—心血管疾病]